Vanda Pharmaceuticals Announces Positive Results From Second Phase III Study Of Tradipitant, Confirming Efficacy In Preventing Motion Sickness-Related Vomiting
Vanda Pharmaceuticals Announces Positive Results From Second Phase III Study Of Tradipitant, Confirming Efficacy In Preventing Motion Sickness-Related Vomiting
萬達製藥宣佈Tradipitant的第二期III期研究取得積極結果，證實了預防暈車相關嘔吐的功效
- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the results from its second Phase III study of tradipitant in motion sickness, confirming the previously reported results of two efficacy studies demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness. This Phase III study was conducted in real-world conditions on boats in the coastal waters of the United States (U.S.).
- 萬達製藥公司（Vanda）（納斯達克股票代碼：VNDA）今天公佈了其對傳統藥物治療暈車的第二項III期研究的結果，證實了先前報告的兩項療效研究的結果，這些研究表明，傳統藥物可有效預防與暈車相關的嘔吐。這項第三階段研究是在美國（美國）沿海水域的船隻的真實條件下進行的。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。